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Methods
The authors declare that all supporting data are available within the article and its online-only Data Supplement. A literature review was conducted according to PRISMA guidelines and performed between June 2015 and March 2018 using PubMed with the term stroke and thrombolysis/thrombolytic therapy/recombinant tissue plasminogen activator/tissue plasminogen activator/alteplase/r-tPA/tPA/recanalization, combined with names of individual NOACs (dabigatran, rivaroxaban, apixaban, or edoxaban), novel oral anticoagulant, nonvitamin K antagonist oral anticoagulant, direct oral anticoagulant, direct thrombin inhibitor, factor Xa inhibitor, or idarucizumab as title words or key words. The study flow diagram is shown in Figure I in the online-only Data Supplement. We limited to studies in humans, published in English. Because indications of endovascular treatment may not be generalizable to intravenous approach, we focused on intravenous tPA when data on route were available. A standard form was developed to extract patient demographics, key time intervals, laboratory tests, initial National Institutes of Health Stroke Scale, use of idarucizumab, symptomatic intracranial hemorrhage (sICH), and outcomes ≤3-month follow-up. Based on the NINDS trial criteria and data availability, 2 National Institutes of Health Stroke Scale score ≤1, modified Rankin Scale score 0 to 2, or neurological improvement in National Institutes of Health Stroke Scale score ≥8 points were considered as favorable outcome.
Except for 2 large multicenter cohorts, 3, 4 most studies were case reports or case series. Because of potential publication bias, treatment selection, small sample size, lack of control, or lack of adjusted results, we did not perform a meta-analysis by pooling study odds ratios. Instead, we summarized characteristics and reported outcomes in the entire sample. Because the results of each NOAC are not comparable in this type of review, individual NOAC outcomes were not reported separately, except for dabigatran with idarucizumab because it represents an up-to-date information. The Institutional Review Board of Duke University approved the study.
Results

Baseline Characteristics
We identified 55 studies with a total of 492 NOAC patients (181 dabigatran, 215 rivaroxaban, 40 apixaban, and 56 unspecified NOAC agent) receiving stroke recanalization therapy (Table I in the online-only Data Supplement). Among patients with complete individual-level data, the median age was 77 years (interquartile range, 68-83; n=73), the median National Institutes of Health Stroke Scale score was 10 (interquartile range, 6-16; n=75), and the median time from last NOAC intake to stroke onset was 8 hours (interquartile range, 2.5-14.5; n=39; 
Clinical Outcomes
The overall observed rates of sICH, mortality, and favorable outcomes were 4.3% (20/462), 11.3% (48/423), and 43.7% (164/375), respectively ( 
Discussion
The current guidelines caution against administrating intravenous tPA to patients taking NOACs unless sensitive laboratory tests are normal or the last intake of NOACs is >48 hours before stroke. 1 However, this recommendation is complex to implement because of the lack of rapidly available sensitive tests. Global coagulation tests, such as PT, aPTT, and INR are not specific for NOACs. 5 Indeed, few patients in this review received tPA based on sensitive test results, such as thrombin time or anti-Xa assays. Interestingly, most patients with last NOAC intake documented had NOAC within 24 hours before stroke (55.2% within 12 hours and 33.9% between 13 and 24 hours), which was shorter than the recommended 48-hour window. Although few cases in this review were treated with tPA according to guideline recommendations, the observed sICH rates seem to be comparable with those reported in nonanticoagulated patients in clinical trials. Therefore, this review contributes to the growing body of evidence that patients taking NOACs may not have an increased bleeding risk after tPA adminstration. 6 With the introduction of idarucizumab in 2015 and andexanet alfa in 2018, patients taking NOACs may undergo reversal of anticoagulation, potentially reducing bleeding risk. In our review of 152 cases with dabigatran, those reversed with idarucizumab appeared less likely to bleed (4.5% versus 7.4%) and die (4.5% versus 12.0%) and more likely to have favorable outcomes (79.1% versus 39.2%) than those not. These findings suggest that intravenous tPA after idarucizumab reversal is a reasonable option to consider in patients on dabigatran even though a prothrombotic effect cannot be completed excluded. 7 Further studies are needed to evaluate the safety and efficacy of anticoagulation reversal before tPA administration.
Our study has limitations. First, this review is based mostly on case reports or case series. Publication bias and treatment selection are likely significant and potentially overestimate or underestimate the true bleeding risk. Second, small sample size, lack of control groups, and only aggregate data in some studies prevent us from doing risk adjustment or running suitable meta-analyses. Third, owing to the nature of case reports and word limits imposed by various journals, patient-level details are often incomplete. Therefore, a direct comparison between NOAC versus no oral anticoagulants, NOAC versus warfarin, or between each individual NOAC agent cannot be made.
In conclusion, this present review suggests that use of intravenous tPA in selected patients with acute ischemic stroke treated with NOACs is feasible and appears to be well tolerated without prohibitive risks for bleeding complications. Reversal of anticoagulant effects by idarucizumab is an emerging strategy that was associated with more favorable outcomes. Further prospective studies and clinical trials are needed to evaluate the safety and efficacy of tPA in patients with ischemic stroke who are taking NOACs.
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